Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Meiosis-specific with OB-fold protein (MEIOB) is a chromatin-associated, meiosis-specific, single-stranded DNA (ssDNA) binding protein that exhibits 3′–5′ exonuclease activity[1][2][3]. It forms a complex with SPATA22 and interacts with the replication protein A (RPA) heterotrimer, functions crucial for stabilizing recombination intermediates during meiotic homologous recombination[1][2]. Mutations in MEIOB can cause infertility in both sexes by blocking homologous recombination and leading to gametogenic arrest[1][2][3]. MEIOB is evolutionarily conserved and most abundantly expressed in gametogenic tissues, particularly the testis, and is required for double-strand break repair during meiosis but is not present or functional in somatic tissues[1][2][3]. Currently, no approved or experimental drugs directly target this protein, and it is not considered a therapeutic target in conventional pharmacologic contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Meiosis-specific with OB-fold protein (MEIOB).